ArticleESC heart failure2023
Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Prognostic value of circulating glypican-4 in chronic heart failure.Journal of molecular medicine (Berlin, Germany) · 2026Article
- MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.Circulation · 2026Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Presence of transthyretin amyloidosis cardiomyopathy influences the prognosis of patients with acute decompensated heart failure undergoing cardiac rehabilitation.Journal of physical therapy science · 2025Article
- Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy.ESC heart failure · 2025Article
- Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis.ESC heart failure · 2025Article
- First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.ESC heart failure · 2024Article
- Prevalence of Transthyretin Amyloid Cardiomyopathy Among Acute Heart Failure Patients with Hypertrophy Across the Left Ventricular Ejection Fraction Spectrum.Journal of clinical medicine · 2024Article
- A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Frontiers in medicine · 2024Review
- Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCardiac amyloidosis (CA) is an under-diagnosed cause of heart failure (HF) and has a worse prognosis than other forms of HF. The frequency of death or rehospitalization following discharge for acute heart failure (AHF) in CA (relative to other causes) has not been documented. The study aims to compare hospital readmission and death rates 90 days after discharge for AHF in patients with vs. without CA and to identify risk factors associated with these events in each group. METHODS AND
resultsPatients with HF and CA (HF + CA+) were recruited from the ICREX cohort, after screening of their medical records. The cases were matched 1:5 by sex and age with control HF patients without CA (HF + CA-). There were 27 HF + CA + and 135 HF + CA- patients from the ICREX cohort included in the study. Relative to the HF + CA- group, HF + CA+ patients had a higher heart rate (P = 0.002) and N-terminal prohormone of brain natriuretic peptide levels (P < 0.001) and lower blood pressure (P < 0.001), weight, and body mass index values (P < 0.001) on discharge. Ninety days after discharge, the HF + CA+ group displayed a higher death rate, a higher all-cause hospital readmission rate, and a higher hospital readmission rate for AHF. Death and hospital readmissions occurred sooner after discharge in the HF + CA+ group than in the HF + CA- group.
conclusionsThe presence of CA in patients with HF was associated with a three-fold greater risk of death and a two-fold greater risk of all-cause hospital readmission 90 days after discharge. These findings emphasize the importance of close, active management of patients with CA and AHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.